PMID- 25074447
OWN - NLM
STAT- MEDLINE
DCOM- 20150811
LR  - 20221207
IS  - 1432-2072 (Electronic)
IS  - 0033-3158 (Linking)
VI  - 232
IP  - 3
DP  - 2015 Feb
TI  - The BDNF Val(66)Met polymorphism is associated with escitalopram response in 
      depressed patients.
PG  - 575-81
LID - 10.1007/s00213-014-3694-z [doi]
AB  - BACKGROUND: The brain-derived neurotrophic factor (BDNF) gene is a candidate gene 
      in therapeutic responses to antidepressants. The aim of the study was to 
      determine the effects of BDNF allelic variability on responses to escitalopram 
      treatment at 3 weeks after treatment initiation and at a 6-week endpoint. 
      METHODS: We included 187 Caucasian subjects with depression; 153 completed the 
      6-week study. Clinical evaluation was performed using the Montgomery and Asberg 
      Depression Rating Scale (MADRS) before and after 3-6 weeks of treatment. RESULTS: 
      After 3 weeks of treatment, we saw significantly better treatment responses in 
      the Met carriers and greater antidepressant resistance among the Val/Val 
      homozygotes. Relative to Val/Val homozygous (59.78 %), a significantly greater 
      proportion of subjects Met-carriers (77.94 %) responded to escitalopram treatment 
      (chi (2) = 5.88, p = 0.015). After 6 weeks, we found the same pattern of results 
      but this effect did not reach statistical significance (chi (2) = 2.07, p = 0.15). 
      CONCLUSION: These findings highlight a significant association between the BDNF 
      valine to methionine substitution (Val(66)Met) polymorphism and the treatment 
      response to escitalopram in a Caucasian population of severely depressed 
      inpatients.
FAU - El-Hage, Wissam
AU  - El-Hage W
AD  - Clinique Psychiatrique Universitaire, Centre Expert Depression Resistante, 
      Fondation FondaMental, CHRU de Tours, 37044, Tours Cedex 9, France, 
      wissam.elhage@univ-tours.fr.
FAU - Vourc'h, Patrick
AU  - Vourc'h P
FAU - Gaillard, Philippe
AU  - Gaillard P
FAU - Leger, Julie
AU  - Leger J
FAU - Belzung, Catherine
AU  - Belzung C
FAU - Ibarguen-Vargas, Yadira
AU  - Ibarguen-Vargas Y
FAU - Andres, Christian R
AU  - Andres CR
FAU - Camus, Vincent
AU  - Camus V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140731
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 0DHU5B8D6V (Citalopram)
RN  - AE28F7PNPL (Methionine)
RN  - HG18B9YRS7 (Valine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Citalopram/administration & dosage/*pharmacology
MH  - Depressive Disorder, Major/*drug therapy/*genetics
MH  - Female
MH  - Humans
MH  - Male
MH  - Methionine/genetics
MH  - Middle Aged
MH  - Polymorphism, Genetic
MH  - Selective Serotonin Reuptake Inhibitors/administration & dosage/*pharmacology
MH  - Treatment Outcome
MH  - Valine/genetics
MH  - Young Adult
EDAT- 2014/07/31 06:00
MHDA- 2015/08/12 06:00
CRDT- 2014/07/31 06:00
PHST- 2014/02/27 00:00 [received]
PHST- 2014/07/12 00:00 [accepted]
PHST- 2014/07/31 06:00 [entrez]
PHST- 2014/07/31 06:00 [pubmed]
PHST- 2015/08/12 06:00 [medline]
AID - 10.1007/s00213-014-3694-z [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2015 Feb;232(3):575-81. doi: 
      10.1007/s00213-014-3694-z. Epub 2014 Jul 31.